Germany · Delayed Price · Currency is EUR Rohto Pharmaceutical Statistics
Total Valuation
FRA:UC1 has a market cap or net worth of EUR 2.94 billion. The enterprise value is 2.92 billion.
| Market Cap | 2.94B |
| Enterprise Value | 2.92B |
Important Dates
The last earnings date was Thursday, February 12, 2026.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | Sep 29, 2025 |
Share Statistics
| Current Share Class | 225.96M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.58% |
| Shares Change (QoQ) | +2.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 200.75M |
Valuation Ratios
The trailing PE ratio is 15.68.
| PE Ratio | 15.68 |
| Forward PE | n/a |
| PS Ratio | 1.61 |
| PB Ratio | 1.78 |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 15.54 |
| EV / Sales | 1.58 |
| EV / EBITDA | 9.36 |
| EV / EBIT | 13.18 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.03, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.03 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 0.92 |
| Debt / FCF | n/a |
| Interest Coverage | 30.89 |
Financial Efficiency
Return on equity (ROE) is 12.20% and return on invested capital (ROIC) is 11.04%.
| Return on Equity (ROE) | 12.20% |
| Return on Assets (ROA) | 5.80% |
| Return on Invested Capital (ROIC) | 11.04% |
| Return on Capital Employed (ROCE) | 11.43% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 199,489 |
| Profits Per Employee | 20,520 |
| Employee Count | 9,144 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 2.31 |
Taxes
In the past 12 months, FRA:UC1 has paid 63.66 million in taxes.
| Income Tax | 63.66M |
| Effective Tax Rate | 25.14% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 13.79 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 31.77 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:UC1 had revenue of EUR 1.82 billion and earned 187.63 million in profits. Earnings per share was 0.81.
| Revenue | 1.82B |
| Gross Profit | 1.02B |
| Operating Income | 217.79M |
| Pretax Income | 253.19M |
| Net Income | 187.63M |
| EBITDA | 307.34M |
| EBIT | 217.79M |
| Earnings Per Share (EPS) | 0.81 |
Balance Sheet
The company has 402.52 million in cash and 281.34 million in debt, with a net cash position of 121.18 million.
| Cash & Cash Equivalents | 402.52M |
| Total Debt | 281.34M |
| Net Cash | 121.18M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.66B |
| Book Value Per Share | 6.91 |
| Working Capital | 615.19M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 56.13%, with operating and profit margins of 11.94% and 10.29%.
| Gross Margin | 56.13% |
| Operating Margin | 11.94% |
| Pretax Margin | 13.88% |
| Profit Margin | 10.29% |
| EBITDA Margin | 16.85% |
| EBIT Margin | 11.94% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 20.12, which amounts to a dividend yield of 157.19%.
| Dividend Per Share | 20.12 |
| Dividend Yield | 157.19% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 2,492.43% |
| Buyback Yield | -1.58% |
| Shareholder Yield | 153.19% |
| Earnings Yield | 6.38% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:UC1 has an Altman Z-Score of 4.13 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.13 |
| Piotroski F-Score | 3 |